Gilead Sciences, Inc. (NASDAQ:GILD)’s shares increased 1.69% to $70.20. The company on Mar. 28 announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1, 2014 entirely in cash. In accordance with the foregoing, Gilead notified Wells Fargo Bank, National Association, the Trustee for the Notes, that it had designated a “Cash Percentage” (as defined in the indenture governing the Notes (the “Indenture”)) of 100% to apply to the “Daily Share Amount” for every “Trading Day” during the relevant “Conversion Reference Period” (each as defined in the Indenture) applicable to the Notes. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $70.62 moved to $70.11 on last trade day and at the end of the day closed at $68.55. Company price to sales ratio in past twelve months was calculated as 9.39 and price to cash ratio as 49.33. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -4.88%.
Xalkori from Pfizer Inc. (NYSE:PFE) cleared the Phase 3 trial for first-line therapy against non-small cell lung cancer (NSCLC). The drug candidate showed superior results compared to chemotherapy in previously untreated patients. Pfizer Inc. (NYSE:PFE) shares fell -0.69% in last trading session and ended the day on $31.88. PFE return on equity ratio is recorded as 52.60% and its return on assets is 23.20%. Pfizer Inc.(NYSE:PFE) yearly performance is 14.10%.
Merck (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. The global market for Hepatitis C treatment is growing, and Gilead Sciences is at its forefront. Given that a lot of major drugs have lost their patent protection in recent years, it is imperative for Merck to find new avenues for growth. A successful Hepatitis C drug launch might just be what Merck needs in the coming years. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.45% in last trading session and was closed at $55.98, while trading in range of $55.77 – 56.96 . Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 12.37%.
The Department of Justice is reviewing a request to investigate Johnson & Johnson (NYSE:JNJ) over destruction of potential evidence in a civil matter. While Johnson & Johnson (NYSE:JNJ) had dismissed the destroyed documents as “inadvertent loss of certain, limited documents,” those fighting the company on the issue regarding pelvic implants accused of harming women have a different view. Johnson & Johnson (NYSE:JNJ) weekly performance is 1.57%. On last trading day company shares ended up $97.44. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average (SMA50) is 5.89%. Analysts mean target price for the company
is $101.08.
Leave a Reply